Companies›Consumer Discretionary›Consumer Services›Retailing

TAVEXIA LIFECARE LIMITED

Consumer Services › Retailing
₹1.18
at close · 8 Oct 2026
▼ 0.02 (-1.67%)

Latest filings

  1. Board approves 60% acquisition of Meyonex Pharmaceuticals for Rs 67.19 crore · Board & Shareholder Meetings
  2. Tavexia Lifecare to acquire 60% in Meyonex Pharma for Rs 67.19 cr · Board & Shareholder Meetings
  3. 46th AGM: All 4 resolutions passed including Rs 100 Cr RPT approval · Compliance
All filings ↓
Ask Nexa about TAVEXIA LIFECARE LIMITED

Snapshot

What the business is, and whether it's a good one at a fair price.

A Retailing company listed on BSE, reporting revenue of ₹32 Cr over the trailing twelve months.

Market Cap
₹46 Cr
P / E (TTM)
8.0×
EV / EBITDA
65.3×
Div Yield
—
Growth
—·
Revenue 5y CAGR
PAT — · EBITDA —
Quality
5.2%·
ROCE (5y median)
ROE 3.8% (5y median) · margin 2.3%
Leverage
0.08·
Debt / Equity · low
Net debt ₹3.51 Cr
Revenue FY22→FY26
20.9×▲
Margin −0.6 pts
₹2 Cr → ₹32 Cr
Cash conversion
-4.11×▼
Operating cash ÷ profit · 5 yrs
₹-18 Cr on ₹4 Cr
Moves on a normal day
1.33%·
Median daily move
Last 268 sessions · the yardstick for filing-day moves
Where it sits among 65 Retailing peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#13/52
P/B#17/50
ROCE#46/63
ROE#38/49
Debt / Equity#26/49
EBITDA margin#48/50
Revenue growth#1/51
Profit growth#45/46

Scorecard

Measured from the filed financials, judged against its Retailing peers · as of FY26 — not investment advice

Strengths
Negative working-capital cycle — the business is funded by its suppliers
Concerns
Returns on capital 5.2% (5-year median)
#46 of 63 in Retailing on the latest reported figures
Over 5 years it reported ₹4.50 Cr of profit and an operating cash outflow of ₹18 Cr — -4.11×
Less than 60p of every ₹1 of profit arrived as cash

Charts

How has the market priced it — with filings on the timeline?

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from TAVEXIA LIFECARE LIMITED's filed financials and exchange disclosures

What does TAVEXIA LIFECARE LIMITED do?

TAVEXIA LIFECARE LIMITED is a Retailing company listed on BSE.

Is TAVEXIA LIFECARE LIMITED profitable?

No. Over the trailing twelve months TAVEXIA LIFECARE LIMITED reported a net loss of ₹0.09 Cr on revenue of ₹32 Cr.

Does TAVEXIA LIFECARE LIMITED pay a dividend?

Not in the latest reported year — TAVEXIA LIFECARE LIMITED's dividend payout for FY26 was nil.

Is TAVEXIA LIFECARE LIMITED debt-free?

No. It reported borrowings of ₹3.51 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹3.51 Cr after cash. Debt stands at 0.08× equity. That is higher than 52% of its 49 Retailing peers.

Is TAVEXIA LIFECARE LIMITED expensive compared with its peers?

On trailing P/E, TAVEXIA LIFECARE LIMITED ranks 13 of 52 in Retailing — cheaper than 77% of them, against an industry median of 23.7×. This is a position, not a valuation judgement.

How much does the TAVEXIA LIFECARE LIMITED share price move in a day?

On a typical session TAVEXIA LIFECARE LIMITED moves 1.33% — that is the median absolute close-to-close move across its last 268 trading days. MarketPing measures each filing's price reaction against it.

Where can I track TAVEXIA LIFECARE LIMITED's announcements?

Every NSE and BSE filing by TAVEXIA LIFECARE LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.